Suppliers and packagers for generic pharmaceutical drug: APOMORPHINE HYDROCHLORIDE

APOMORPHINE HYDROCHLORIDE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Mdd Us	APOKYN	apomorphine hydrochloride	INJECTABLE;SUBCUTANEOUS	021264	NDA	MDD US Operations, LLC	27505-004-05	5 CARTRIDGE in 1 CARTON (27505-004-05) / 3 mL in 1 CARTRIDGE (27505-004-01)	2004-07-02
Tp Anda Holdings	APOMORPHINE HYDROCHLORIDE	apomorphine hydrochloride	INJECTABLE;SUBCUTANEOUS	212025	ANDA	TruPharma, LLC	52817-720-05	5 CARTRIDGE in 1 CARTON (52817-720-05) / 3 mL in 1 CARTRIDGE (52817-720-01)	2022-02-24
Mdd Us	ONAPGO	apomorphine hydrochloride	SOLUTION;SUBCUTANEOUS	214056	NDA	MDD US Operations, LLC, a subsidiary of Supernus Pharmaceuticals, Inc	27505-006-05	5 CARTRIDGE in 1 CARTON (27505-006-05) / 20 mL in 1 CARTRIDGE (27505-006-01)	2025-02-04

Suppliers and packagers for generic pharmaceutical drug: APOMORPHINE HYDROCHLORIDE

Last updated: May 26, 2026

Apomorphine Hydrochloride Suppliers (API, Drug Product, and Contract Manufacturing)

Executive summary: Apomorphine hydrochloride is supplied through a mix of originator-branded manufacturers, generic drug product makers, and specialty API and intermediate suppliers. For commercial readiness (FDA injectable and oral film/tablet formats, plus device-ready pump systems where applicable), the practical supplier set breaks into (1) injectable apomorphine hydrochloride drug product manufacturers, (2) apomorphine hydrochloride API/intermediate suppliers, and (3) packaging and secondary assembly providers for autoinjector or infusion delivery systems.

What matters operationally: apomorphine is high-scrutiny due to strong cold-chain and handling expectations for injectable quality systems, narrow dosing adjustments, and downstream requirements for combination device configurations in some markets.

Which companies supply apomorphine hydrochloride drug product (injection) for global markets?

Featured snippet answer: Major apomorphine hydrochloride injectable supply is dominated by branded and generic drug product manufacturers that list on national formularies and supply to distributors for Parkinson’s disease indications. The supply chain is typically split by country and dosage form.

Common branded and generic supply routes

In practice, “supplier” means one of three entities:

1. Drug product manufacturer (apomorphine hydrochloride injection fill-finish, sterile manufacturing, labeling).
2. Parallel importer / wholesaler (distribution, not manufacture).
3. Contract manufacturing organization (CMO) for sterile fill-finish and secondary packaging.

Injection supply considerations

• Sterility assurance: terminal sterilization feasibility varies by formulation; aseptic processing is common in specialty injectables.
• Dose-volume usability: pump-ready delivery requires compatible packaging and labeling.
• Cold-chain handling: supplier logistics terms matter because apomorphine formulations are sensitive to excursion and handling.

Who supplies apomorphine hydrochloride API (active pharmaceutical ingredient) for contract production?

Featured snippet answer: API procurement for apomorphine hydrochloride is handled through a limited set of specialty chemical/API suppliers capable of producing apomorphine-related intermediates and the finished API with validated impurity profiles.

API supply chain structure

Most API procurement flows through:

• Apomorphine hydrochloride API producers (finished API to DMF/EDMF linked dossiers where applicable).
• Intermediate makers feeding API producers (stepwise synthesis with controlled impurity carryover).
• Re-packers that break bulk only, typically not the synthesis owner.

Audit and qualification points

• Residual solvent compliance
• Impurity and degradation product control strategy
• Batch consistency (LC methods, impurity thresholds, and stability-indicating assays)

What patents protect apomorphine hydrochloride suppliers and their manufacturing (API, formulations, and methods)?

Featured snippet answer: Apomorphine hydrochloride is an established active ingredient, so active patent coverage is mainly residual around formulations, delivery systems, and manufacturing controls, not the base molecule in most jurisdictions.

Patent estate typically targets

• Dosage form and composition (stabilizers, buffers, pH control, tonicity)
• Device-enabled delivery (pump/needle systems where combination is used in practice)
• Method-of-use (often framed around Parkinson’s disease treatment paradigms)

Supplier impact

• Generic drug product suppliers usually rely on process freedom to manufacture API and freedom-to-operate in formulation.
• For device-centric products, supply access can be constrained by combination IP and packaging-specific trade dress.

What is the FDA and Orange Book status of apomorphine hydrochloride products (and how does that affect supplier selection)?

Featured snippet answer: FDA listings and Orange Book status determine whether new entrants face exclusivity blocks, unexpired patents, and labeling constraints that influence who can manufacture and sell specific apomorphine drug products in the US.

Supplier selection driven by regulatory posture

A sourcing strategy usually stratifies by:

• US market access: whether a product is listed with patents and if Paragraph IV is involved.
• Label alignment: dose strength, administration instructions, and compatibility statements.
• Supply continuity risk: reliance on a single sterile fill-finish site can create disruption exposure.

How do supply chains differ for apomorphine hydrochloride injections vs other dosage forms?

Featured snippet answer: Injection sourcing is constrained by sterile manufacturing and validated compatibility; oral or other dosage forms (where marketed in specific regions) shift the supplier constraint to coating, film/tablet process control, and stability.

Injection supplier stack

• Sterile drug substance delivery (API)
• Aseptic fill-finish (or terminal sterilization if formulation allows)
• Vial/ampoule primary container and carton assembly
• Labeling and cold-chain compliant logistics

Oral dosage supplier stack (if applicable in a region)

• Granulation and tableting or film casting
• Stability for pH and humidity
• Taste-masking or excipient strategy (where used)
• Packaging with moisture barrier controls

When do apomorphine hydrochloride exclusivity and patent barriers expire for new generic or CMO capacity?

Featured snippet answer: Timing to market for apomorphine hydrochloride suppliers is mostly driven by product-specific patent and exclusivity rather than API molecule status.

What to check in a supplier due diligence timeline

• Patent expiration windows for:
  • formulation
  • method-of-use
  • device integration
  • manufacturing process (where claimed)
• Regulatory exclusivity blocks tied to:
  • application type (505(b)(2), 505(j), 505(b)(1))
  • clinical data packages

What Paragraph IV challenges and apomorphine hydrochloride litigation affect supplier entry?

Featured snippet answer: Supplier entry risk depends on whether current drug product patents are actively challenged or enforced in litigation.

Why it matters for sourcing

• A CMO’s ability to supply depends on whether the client’s product can launch without injunction risk.
• Distribution contracts may carry indemnity obligations if patents are not cleared.

How many suppliers are viable for apomorphine hydrochloride (API and drug product), and what are typical bottlenecks?

Featured snippet answer: The viable supplier base is limited by specialized synthetic capability (API) and sterile fill-finish capacity (drug product). Bottlenecks typically occur in:

• validated sterile aseptic suites
• validated container-closure systems
• impurity-controlled API lots

Bottlenecks by step

Step	Primary bottleneck	Typical mitigation
API synthesis	impurity control and batch consistency	qualification of multiple API lots and reserve suppliers
Aseptic fill-finish	sterile capacity and QC release testing	multiple campaigns across two CMOs
Device-ready packaging	compatibility and assembly QA	audited assembly houses and serialized packaging controls
Regulatory tech transfer	method validation and analytical bridging	prebuilt tech transfer packages and comparator data

Which geographic regions supply apomorphine hydrochloride most reliably?

Featured snippet answer: Reliable apomorphine hydrochloride supply tends to concentrate in regions with mature sterile manufacturing ecosystems and established chemical/API capability.

Commercially relevant sourcing patterns

• US/EU-oriented drug product manufacturers: higher QA documentation alignment with FDA and EMA expectations.
• Global API synthesis hubs: supply can be strong for cost, but may face DMF alignment and impurity specification tightening for specific finishers.

What is the compliance burden for apomorphine hydrochloride suppliers (GMP, QC release, comparability)?

Featured snippet answer: Apomorphine hydrochloride injectable supply requires strict GMP-aligned sterility, analytics, and stability programs.

Due diligence checkpoints

• Sterility assurance strategy (media fills, environmental monitoring)
• Analytical methods transfer completeness (assay, impurities, degradation products)
• Container-closure integrity and hold-time studies
• Stability indicating method performance

Key Takeaways

• Apomorphine hydrochloride supply is split between sterile injection drug product manufacturers and specialty API/intermediate suppliers.
• Supplier qualification is mainly constrained by aseptic/sterile manufacturing capability, impurity-controlled API, and product-specific regulatory status.
• Patent and exclusivity barriers are typically product/formulation/device-specific, so entry risk for new suppliers depends on the exact marketed presentation and labeling.

FAQs

1. Which firms commonly manufacture apomorphine hydrochloride injectable drug product under contract?
2. How does apomorphine hydrochloride API qualification differ from sterile drug product fill-finish qualification?
3. What documentation is required to transfer an apomorphine hydrochloride injection manufacturing process to a new CMO?
4. Do apomorphine hydrochloride products face device-combination IP constraints in any markets?
5. What are the main QC release tests used for apomorphine hydrochloride injectables?

References

1. FDA, Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
2. FDA Drug Applications: Drug Approval Reports and application databases. U.S. Food and Drug Administration.
3. EMA product information and EPAR filings for apomorphine-containing medicines. European Medicines Agency.